Centrinone-B

• Description :

  Centrinone-B (LCR-323) is a potent and highly selective PLK4 inhibitor, with a Ki of 0.59 nM.

• Product Name Alternative :

  LCR-323

• UNSPSC :

  12352005

• Hazard Statement :

  H302

• Target :

  Polo-like Kinase (PLK)

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Centrinone-B.html

• Purity :

  98.65

• Solubility :

  DMSO : 25 mg/mL (ultrasonic)

• Smiles :

  FC(C([N+]([O-])=O)=CC=C1)=C1CS(C2=CC(F)=C(SC3=NC(NC4=NNC(C)=C4)=C(OC)C(N5CCCCC5)=N3)C=C2)(=O)=O

• Molecular Formula :

  C27H27F2N7O5S2

• Molecular Weight :

  631.67

• Precautions :

  H302

• References & Citations :

  [1]Wong YL, et al. Cell biology. Reversible centriole depletion with an inhibitor of Polo-like kinase 4. Science. 2015 Jun 5;348 (6239) :1155-60.|[2]Denu RA, et al. Centriole Overduplication is the Predominant Mechanism Leading to Centrosome Amplification in Melanoma. Mol Cancer Res. 2018 Jan 12.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  PLK4

• CAS Number :

  [1798871-31-4]